Off-Label 16-mm VSD Occluder for Closure of a Giant PDA With Severe Pulmonary Hypertension Authors: Sachin Sapkota, Purnima Sharma, Kahtan Fadah, Edgar Ivan Usle Perez, Vaishnavi Sabesan, Vishakh Prakash, Jyothsna Goranti, Sandesh Murali, Chalam Mulukutla Published: 2026 ABSTRACT AbstractBackgroundGiant patent ductus arteriosus (PDA) with pulmonary hypertension often presents unique challenges for closure, requiring extensive expert team discussion.Case-SummaryA 17-year-old girl with syncopal episodes, intermittent chest pain, and continuous cardiac murmur was diagnosed with a 12.5-mm PDA. After a few months of pulmonary vasodilator therapy, pulmonary vascular resistance (PVR) improved from 7 WU to 5.5 WU, and treatment with closure using a 16-mm ventricular septal defect (VSD) occluder proceeded. Post-procedure, symptoms resolved along with left ventricular remodeling.DiscussionOff-label use of VSD occluders is increasing for treatment of large PDAs. In high-risk patients, careful hemodynamic assessment, trial occlusion, and staged pulmonary vasodilator therapy optimize outcomes. For controversial borderline PVR (5-8 WU), closure decisions should rely on comprehensive evaluation by adult congenital heart disease and pulmonary hypertension specialists rather than PVR alone.Take-Home MessagesMuscular VSD occluders provide a viable alternative for large PDA closure with complex anatomy. In borderline PVR (5-8 WU), decisions should rely on comprehensive evaluation by adult congenital heart disease and pulmonary hypertension specialists rather than PVR alone.Key words: patent ductus arteriosus, pulmonary hypertension, sildenafil, trial balloon occlusion, ventricular septal defect occluder History of Presentation A 17-year-old girl with no significant past medical history who had relocated from Central America was evaluated in our cardiology clinic for a cardiac murmur. Over the past few months, she reported several syncopal episodes and intermittent chest pain and rare episodes of dyspnea. She denied any palpitations, orthopnea, or lower extremity edema. She reported being diagnosed with patent ductus arteriosus (PDA) during childhood, but her medical records were not available. On physical examination, heart rate was 65 beats/min, blood pressure was 94/60 mm Hg, and oxygen saturation was 98% on room air. The cardiac examination revealed a grade 4, continuous machine -like murmur at the left upper chest, radiating to the axilla. The rest of her systemic examination was unremarkable. Differential Diagnosis Differential diagnosis for continuous murmurs included PDA, venous hum (benign), aortopulmonary window (ascending aorta–main pulmonary artery shunt), coronary artery fistula, pulmonary arteriovenous malformation, and less commonly ruptured sinus of Valsalva aneurysm. The clinical presentation was most consistent with a hemodynamically significant PDA with potential pulmonary vascular disease. Investigations Transthoracic echocardiography demonstrated left ventricular dilation and elevated pulmonary artery pressure. Color Doppler imaging confirmed a large PDA (Video 1). The patient was referred for diagnostic cardiac catheterization to further access shunt magnitude, pulmonary vascular resistance (PVR), and ductal dimensions. The patient underwent right and left heart catheterization with PDA angiography (Video 2). PDA diameter was 12.5 mm, pulmonary/systemic flow ratio (Qp/Qs) was 2.5:1, PVR was 7 WU with transpulmonary gradient of 20 mm Hg, raising concern for developing pulmonary vascular disease. A significant oxygen saturation step-up from superior vena cava to pulmonary artery confirmed a large left-to-right shunt. Management Medical therapy After discussion with the pulmonary hypertension team, medical therapy was initiated with sildenafil 20 mg 3 times daily to reduce pulmonary vascular resistance before attempting device closure. The patient tolerated therapy well over several months. Medical decision making Adult congenital heart disease and pulmonary hypertension specialists reassessed the situation and advised proceeding with repeat PDA angiography and possibly transcatheter PDA closure. After a detailed discussion of risks, benefits, and alternatives, informed consent was obtained. Transcatheter closure procedure Repeat PDA angiography and hemodynamic evaluation were performed. Stepwise hemodynamic evaluation was carried out under sequential conditions (Table 1): baseline with room air, 100% fraction of inspired oxygen along with 20 ppm inhaled nitric oxide, 24-mm balloon occlusion test, and after device deployment. Throughout these phases, oxygen saturation levels improved (PA saturation from left distal PA; aortic saturation from descending aorta), Qp/Qs improved, and pulmonary artery pressures and transpulmonary gradient decreased, indicating a favorable physiologic state for ductal closure. Significantly, test occlusion led to a decrease in right ventricular (RV) systolic pressure (from 80 mm Hg to 60 mm Hg) and wedge pressure, whereas systemic oxygen saturation was maintained and aortic pressure increased—factors that indicate hemodynamic tolerance to closure (Table 1). PVR after the trial occlusion was calculated as 5.5 WU, which is above the 2025 American College of Cardiology/American Heart Association (ACC/AHA) recommended threshold. However, closure was advised based on a case-based assessment of shunt severity, left ventricular overload, progressive pulmonary vascular disease risk, and pulmonary arterial hypertension (PAH) therapy response. Considering the 12.5-mm PDA diameter with a shorter and wider defect, a 16-mm Amplatzer Muscular VSD Occluder (Abbott Structural Heart) was chosen for off-label closure due to its larger waist diameter compared with standard PDA occluders, its dual-disc design that offers secure anchoring, and its established safety in other structural heart interventions. In view of the PDA distensibility of up to 15 mm observed during the balloon occlusion test, a slightly oversized occluder was chosen to optimize device stability. Table 1Intraprocedural Hemodynamic and Oxygen Saturation Measurements∗Room Air (Fio2 21%)100% Fio2 + 20 ppm NOTest Occlusion (24-mm Balloon)After Device PlacementRA saturation, %738073—RV saturation, %728171—PA saturation (left distal PA), %899668—Aortic saturation (descending aorta), %959898—RA pressure, mm Hg24/19/22Mean 17——RV pressure, mm Hg82/2275/1760/16SimilarPA pressure, mm Hg81/44/5966/39/5255/35/41SimilarPCWP, mm Hg322720∼20Aortic pressure, mm Hg105/26110/51118/60120/65Qp/Qs2.5:1Improved (favorable step-up)1:1 (CO: 3.85 L/min)1:1CO = cardiac output; Fio2 = fraction of inspired oxygen; NO = nitric oxide; PA = pulmonary artery; PCWP = pulmonary capillary wedge pressure; Qp/Qs = pulmonary/systemic blood flow ratio; RA = right atrium; RV = right ventricle.∗Favorable hemodynamic changes were found during sequential testing conditions supporting the feasibility of PDA closure. Intraprocedural Hemodynamic and Oxygen Saturation Measurements∗ CO = cardiac output; Fio2 = fraction of inspired oxygen; NO = nitric oxide; PA = pulmonary artery; PCWP = pulmonary capillary wedge pressure; Qp/Qs = pulmonary/systemic blood flow ratio; RA = right atrium; RV = right ventricle. Favorable hemodynamic changes were found during sequential testing conditions supporting the feasibility of PDA closure. The aortic and pulmonary discs were successfully deployed with an aggressive push-pull maneuver confirming stability. Post-deployment angiography demonstrated complete PDA occlusion with appropriate device position (Video 3). Outcomes and follow-up The post-procedural hospital course was uneventful. Chest radiograph confirmed correct device positioning (Figure 1). The patient was discharged on furosemide 10 mg daily and continued sildenafil therapy. Post-Procedural Chest Radiograph Demonstrating Stable Device Position Following the procedure, a chest radiograph was obtained, which clearly demonstrates that the ventricular septal defect occluder (arrow) is appropriately positioned within the anatomical region corresponding to the patent ductus arteriosus, confirming accurate device placement and alignment. At 1-month follow-up, the patient reported complete resolution of syncope and chest pain. Vital signs were within normal limits. Systemic and cardiac examinations were unremarkable. Follow-up transthoracic echocardiography demonstrated a well-positioned 16-mm ventricular septal defect (VSD) occluder with complete PDA closure (Video 4) and improved left ventricular size and left ventricular ejection fraction (50%-55%). The patient was advised to continue sildenafil for long-term pulmonary vascular remodeling. Over the next several months she reported complete resolution of her symptoms. Follow-up echocardiogram showed resolution of left ventricular dilation. Discussion Our case demonstrates the successful off-label use of a VSD occluder for closure of a giant PDA in a patient with elevated PVR. Device selection for giant PDA An Amplatzer Duct Occluder has a maximum size of 16 mm. The selection of device, however, depends on anatomical compatibility and hemodynamic factors. In our case, a VSD occluder was selected due to favorable anatomical considerations, including a shorter and wider duct with enlarged pulmonary and aortic ampullary ends. The symmetrical, double-disc design of the device with a short waist provides superior anchoring and stability in high-pressure shunts, resulting in more effective sealing, improved device retention, and reduced risk of residual shunting and device embolization. There is evidence demonstrating successful closure in patients with a large PDA and pulmonary arterial hypertension with off-label use of Amplatzer Muscular VSD Occluder.1, 2, 3 In a 2023 study, Al Ghanimi et al1 reported that muscular VSD occluders were successfully used to close PDAs measuring 11.59 ± 3.15 mm, resulting in favorable outcomes. Staged management with pulmonary vasodilators Due to elevated PVR (7 WU) in our case, a cautious approach was required. The current approach favors staged management, in which pulmonary vasodilator therapy is administered before definitive closure in patients with borderline operability.4,5 Hemodynamic assessment and trial occlusion Rigorous hemodynamic evaluation is critical when closing PDAs in patients with elevated pulmonary pressures. With trial balloon occlusion, it is possible to evaluate in real time the hemodynamic tolerance of closure. In our case, test occlusion showed favorable changes—reductions in RV and pulmonary artery pressures, stable systemic saturation, and an increase in aortic pressure—indicating successful permanent closure could occur without causing right heart failure or a pulmonary crisis. Importantly, a fall in RV systolic pressure during balloon occlusion is not a stand-alone criterion for safe closure; full hemodynamic assessment is required, as it may also indicate acute RV failure. The most controversial criterion in our case was the decision to close the PDA when the PVR was 5.5 WU, which is above the recent 2025 ACC/AHA guideline threshold (IIb recommendation: may be considered if PVR is <5 WU after initiation of PAH therapy).6 However, this recommendation is based on very limited evidence. Our expert team suggested that insufficient evidence existed to mandate a single numeric PVR cutoff (especially on borderline PVR), and thus in the presence of higher Qp/Qs, reassuring trial occlusion response, preserved RV function, and clinical improvement on initial PAH therapy, proceeding with PDA closure along with continued targeted therapy and close follow-up was reasonable. Our team suggested an individualized decision-making process, especially in a patient with borderline PVR (5-8 WU). Sadiq et al7 demonstrated a favorable long-term outcome in PDA closure with PVR ≤8 WU.7 Zhou et al8 found that for adults with large PDAs and severe pulmonary hypertension, a postoperative mean pulmonary artery pressure of <35.5 mm Hg is indicative of favorable long-term outcomes and recommended considering targeted medical therapy if the mean pulmonary artery pressure increased beyond this threshold.8 Armyn et al9 emphasized that trial occlusion can identify patients at risk for adverse pulmonary events, underscoring its role in procedural planning.9 Contemporary guidelines and practice The 2025 ACC guideline supports transcatheter closure as first-line therapy for hemodynamically significant PDAs without specifically covering the choice of device for giant PDAs. The ACC/AHA 2025 guidelines recommend PDA closure for left heart enlargement and net left-to-right shunt with PVR <2 WU (class I) and consider it reasonable for PVR 2 to 5 WU (class IIa). Patients with PVR 5 to 8 WU remain the most controversial as discussed earlier.6 Limitations and future directions We had limited follow-up of 6 months as the patient moved out of our region. Even though the 6-month results were favorable, continued observation is required to assess the long-term effectiveness; alterations in pulmonary vasculature; and potential late complications, such as RV dysfunction, device erosion, or left pulmonary artery stenosis. Future research should assess the long-term effects of off-label VSD occluder use for giant PDAs. Equipment ListDiagnostic equipment • 6-F Multipurpose catheter (Cordis Corporation) • 6-F Pigtail catheter (Cordis Corporation) • 0.035-inch guidewire (Terumo Medical Corporation) • Pressure transducers and hemodynamic monitoring systemImaging equipment • Fluoroscopy system with digital subtraction angiography capability • Transthoracic echocardiography machine (Philips EPIQ 7; Philips Healthcare)Interventional equipment • 24-mm sizing balloon (AGA Medical Corporation) • 16-mm Amplatzer Muscular VSD Occluder (Abbott Structural Heart) • 8-F delivery sheath (Abbott Structural Heart) • Amplatzer delivery cable system (Abbott Structural Heart)Pharmacologic agents • Inhaled nitric oxide 20 ppm • Heparin sodium injection • General anesthesia agents per institutional protocol Conclusions In a patient with high PVR, an off-label application of a 16-mm muscular VSD occluder effectively closed a giant PDA. This case illustrates that staged pulmonary vasodilator therapy, thorough hemodynamic assessment with trial occlusion, and appropriate device choice can lead to favorable outcomes in complex PDA cases. When conventional PDA devices are not suitable for oversized complex ducts, muscular VSD occluders serve as a valuable alternative. For patients with borderline PVR (5-8 WU), closure decisions should be guided by comprehensive evaluation by adult congenital heart disease and pulmonary hypertension specialists rather than relying on PVR alone. Giant PDA Closure Using VSD Device in an Adolescent With Severe Pulmonary Hypertension Off-label transcatheter closure of a giant patent ductus arteriosus (PDA) in a 17-year-old girl with severe pulmonary hypertension using a ventricular septal defect (VSD) occluder, resulting in successful occlusion and improved hemodynamics. ACHD/PH = adult congenital heart disease/pulmonary hypertension; Ao = aortic; LV = left ventricular; PA = pulmonary artery; PVR = pulmonary vascular resistance; Qp/Qs = pulmonary/systemic flow ratio; RV = right ventricular. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. Take-Home Messages •Muscular VSD occluders provide a viable off-label alternative for giant PDA closure when standard devices are unsuitable due to duct size or morphology. Muscular VSD occluders provide a viable off-label alternative for giant PDA closure when standard devices are unsuitable due to duct size or morphology. •For patients with high PVR, the combination of staged pulmonary vasodilator therapy and thorough trial occlusion testing ensures a secure closure. For patients with high PVR, the combination of staged pulmonary vasodilator therapy and thorough trial occlusion testing ensures a secure closure. •In patients with borderline PVR (5-8 WU), decisions should rely on comprehensive evaluation by adult congenital heart disease and pulmonary hypertension specialists rather than PVR alone. In patients with borderline PVR (5-8 WU), decisions should rely on comprehensive evaluation by adult congenital heart disease and pulmonary hypertension specialists rather than PVR alone. Footnotes The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. Appendix For supplemental videos, please see the online version of this paper. Appendix Video 1 Transthoracic Echocardiography Demonstrating Large PDA Initial transthoracic echocardiography demonstrating left ventricular dilation and elevated estimated pulmonary artery pressures. Color Doppler imaging confirms a large patent ductus arteriosus (PDA) with left-to-right shunting. Video 2 Angiographic Assessment of a Large PDA Right and left heart catheterization with patent ductus arteriosus (PDA) angiography demonstrating a large ductus measuring approximately 12 to 12.5 mm in diameter (arrow). Hemodynamic assessment reveals a significant left-to-right shunt with a Qp/Qs ratio of 2.5:1, elevated pulmonary vascular resistance of 7 WU, with concern for evolving pulmonary vascular disease. Video 3 Post-Deployment Angiography Demonstrating Complete PDA Closure Using a VSD Occluder Postprocedural angiography shows successful off-label deployment of a 16-mm ventricular septal defect (VSD) occluder (arrow) across the patent ductus arteriosus (PDA), with stable device positioning and complete occlusion without residual shunt. Video 4 Follow-Up Transthoracic Echocardiography Follow-up transthoracic echocardiography shows a well-seated 16-mm ventricular septal defect occluder with complete patent ductus arteriosus closure without residual shunt. References Associated Data Supplementary Materials Video 1 Transthoracic Echocardiography Demonstrating Large PDA Initial transthoracic echocardiography demonstrating left ventricular dilation and elevated estimated pulmonary artery pressures. Color Doppler imaging confirms a large patent ductus arteriosus (PDA) with left-to-right shunting. Video 2 Angiographic Assessment of a Large PDA Right and left heart catheterization with patent ductus arteriosus (PDA) angiography demonstrating a large ductus measuring approximately 12 to 12.5 mm in diameter (arrow). Hemodynamic assessment reveals a significant left-to-right shunt with a Qp/Qs ratio of 2.5:1, elevated pulmonary vascular resistance of 7 WU, with concern for evolving pulmonary vascular disease. Video 3 Post-Deployment Angiography Demonstrating Complete PDA Closure Using a VSD Occluder Postprocedural angiography shows successful off-label deployment of a 16-mm ventricular septal defect (VSD) occluder (arrow) across the patent ductus arteriosus (PDA), with stable device positioning and complete occlusion without residual shunt. Video 4 Follow-Up Transthoracic Echocardiography Follow-up transthoracic echocardiography shows a well-seated 16-mm ventricular septal defect occluder with complete patent ductus arteriosus closure without residual shunt.